Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CPI-444 Tablet vs Capsule in Healthy Subjects
NCT03237988Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ciforadenant in solid tumor (3 arms), sponsored by Corvus Pharmaceuticals. Primary endpoints: Area under the concentration-time curve from time zero to infinity, Area under the concentration-time curve from time zero to last quantifiable concentration and 1 more. Started Jul 2017; status: completed.
02
Drugs
ciforadenant
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03237988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237988.